reports
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company. Fourth Quarter 2023 Financial Results ...
Synlogic Adopts Limited Duration Stockholders Rights Plan
Synlogic Adopts Limited Duration Stockholders Rights Plan Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of c...
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provid...
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal stu...
Synlogic Announces Publication of Preclinical and Clinical Data for SY...
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting mild-moderate gastrointestinal adverse events CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advanci...
Synlogic Provides Corporate Update and Outlook for 2024
Synlogic Provides Corporate Update and Outlook for 2024 - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1 2025 - CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today summarized accomplishments for 2023 and anticipated key milestones for 2024. “We are pleased w...
Synlogic Announces Contract with the Air Force Research Lab
Synlogic Announces Contract with the Air Force Research Lab - Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology - CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing proces...
Synlogic Announces Abstract Accepted for Poster Presentation at the In...
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 - Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for ...
Synlogic Reports Third Quarter 2023 Financial Results and Provides Cor...
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enrollment completion in 2024, with top-line data in the first half of 2025 - - Company received Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) as a potential treatment for PKU - CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, I...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone ...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced today that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the trea...
Synlogic Announces Closing of $21.0 Million Underwritten Public Offeri...
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering. The offering consisted of 7,394,363 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase up to 7,394,363 shares of common ...
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offeri...
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the pricing of an underwritten public offering of (i) 7,394,363 shares of common stock (or common stock equivalents in lieu thereof) and (ii) accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock. The combined effective offering pric...
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Syntheti...
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU) in the journal Nature Metabolism. The publication, en...
Synlogic Announces Reverse Stock Split
Synlogic Announces Reverse Stock Split CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday, September 27, 2023. The Reverse Stock Split, which was approved by shareholders at the company’s Annual Meeting of Stockholders on September 21, 2023, is primaril...
Synlogic to Participate in Chardan’s Genetic Medicines Conference
Synlogic to Participate in Chardan’s Genetic Medicines Conference CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced its management team will participate in Chardan’s 7th Annual Genetic Medicines Conference, being held in New York, October 2-3, 2023. In addition to one-on-one meetings with investors, Synlogic CEO Dr. Aoife Brennan will participate in a Fireside Chat on Monday, October 2 at 4:30 p...
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that CEO Aoife Brennan, M.B. Ch.B., has been honored as a PharmaVoice 100 winner, a list recognizing the most inspiring people in the life sciences industry. PharmaVoice is a life sciences industry publication operated by Industry Dive that strives to deliver the most important voices...
Synlogic Reports Second Quarter 2023 Financial Results and Provides Bu...
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the second quarter ended June 30, 2023, and provided an update...
Synlogic Granted Fast Track Designation from FDA for labafenogene mars...
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac has also rec...
Synlogic Announces International Nonproprietary Name Selection for SYN...
Synlogic Announces International Nonproprietary Name Selection for SYNB1934 The World Health Organization has approved “labafenogene marselecobac” Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria community CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the International Nonproprietary Names (INN) Expert Committee of the has selected "labafen...
Synlogic Announces Participation in SVB Securities Healthcare Therapeu...
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023. The Synlogic team will be available for one-on-one investor meetings. To register for the conference or request one-on-one meetings...
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST. The Annual Meeting will be held in a virtual meeting format only. Stockholders can access the meeting , vote their shares electronically and submit their questions by entering their 16-digit control number found on the Notice of Int...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.